Veronique Thybaud

Summary

Affiliation: Sanofi-Aventis Deutschland GmbH

Publications

  1. ncbi Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing
    V Thybaud
    Drug Safety Evaluation, Sanofi Aventis, 94400 Vitry sur Seine, France
    Mutat Res 627:41-58. 2007
  2. ncbi Application of toxicogenomics to genetic toxicology risk assessment
    Veronique Thybaud
    Drug Safety Evaluation, sanofi aventis R and D, Vitry sur Seine, France
    Environ Mol Mutagen 48:369-79. 2007
  3. ncbi Strategies in case of positive in vivo results in genotoxicity testing
    Veronique Thybaud
    Sanofi Aventis, Disposition Safety and Animal Research, Vitry sur Seine, France
    Mutat Res 723:121-8. 2011
  4. ncbi Laboratory variability does not preclude identification of biological functions impacted by hydroxyurea
    Arne Muller
    Drug Safety Evaluation, Sanofi Aventis, Vitry sur Seine, France
    Environ Mol Mutagen 46:221-35. 2005
  5. ncbi Relevance and follow-up of positive results in in vitro genetic toxicity assays: an ILSI-HESI initiative
    Veronique Thybaud
    Drug Safety Evaluation, Sanofi Aventis, 94400 Vitry sur Seine, France
    Mutat Res 633:67-79. 2007
  6. ncbi Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling
    Anne Celine Le Fevre
    sanofi aventis R and D, Drug Safety Evaluation, 13 quai Jules Guesde, 94403 Vitry sur Seine Cedex, France
    Mutat Res 619:16-29. 2007
  7. ncbi Cytosine arabinoside, vinblastine, 5-fluorouracil and 2-aminoanthracene testing in the in vitro micronucleus assay with L5178Y mouse lymphoma cells at Sanofi Aventis, with different cytotoxicity measurements, in support of the draft OECD Test Guideline on
    Olivier Cariou
    Drug Safety Evaluation, Sanofi Aventis, Porcheville, France
    Mutat Res 702:148-56. 2010
  8. ncbi Tissue-specific induction of mutations by acute oral administration of N-methyl-N'-nitro-N-nitrosoguanidine and beta-propiolactone to the Muta Mouse: preliminary data on stomach, liver and bone marrow
    D Brault
    Rhone Poulenc Rorer, Drug Safety Department, Vitry sur Seine, France
    Mutat Res 360:83-7. 1996

Collaborators

Detail Information

Publications8

  1. ncbi Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing
    V Thybaud
    Drug Safety Evaluation, Sanofi Aventis, 94400 Vitry sur Seine, France
    Mutat Res 627:41-58. 2007
    ..Although general principles were agreed upon, time did not permit the development of recommendations for the selection of specific tests beyond those commonly employed in initial test batteries...
  2. ncbi Application of toxicogenomics to genetic toxicology risk assessment
    Veronique Thybaud
    Drug Safety Evaluation, sanofi aventis R and D, Vitry sur Seine, France
    Environ Mol Mutagen 48:369-79. 2007
    ....
  3. ncbi Strategies in case of positive in vivo results in genotoxicity testing
    Veronique Thybaud
    Sanofi Aventis, Disposition Safety and Animal Research, Vitry sur Seine, France
    Mutat Res 723:121-8. 2011
    ....
  4. ncbi Laboratory variability does not preclude identification of biological functions impacted by hydroxyurea
    Arne Muller
    Drug Safety Evaluation, Sanofi Aventis, Vitry sur Seine, France
    Environ Mol Mutagen 46:221-35. 2005
    ..The genes identified in our study provide information that is relevant to HU biology...
  5. ncbi Relevance and follow-up of positive results in in vitro genetic toxicity assays: an ILSI-HESI initiative
    Veronique Thybaud
    Drug Safety Evaluation, Sanofi Aventis, 94400 Vitry sur Seine, France
    Mutat Res 633:67-79. 2007
    ....
  6. ncbi Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling
    Anne Celine Le Fevre
    sanofi aventis R and D, Drug Safety Evaluation, 13 quai Jules Guesde, 94403 Vitry sur Seine Cedex, France
    Mutat Res 619:16-29. 2007
    ..Our results suggest that these marker genes could be used as a predictive model to classify genotoxins according to their direct or indirect interaction with DNA...
  7. ncbi Cytosine arabinoside, vinblastine, 5-fluorouracil and 2-aminoanthracene testing in the in vitro micronucleus assay with L5178Y mouse lymphoma cells at Sanofi Aventis, with different cytotoxicity measurements, in support of the draft OECD Test Guideline on
    Olivier Cariou
    Drug Safety Evaluation, Sanofi Aventis, Porcheville, France
    Mutat Res 702:148-56. 2010
    ....
  8. ncbi Tissue-specific induction of mutations by acute oral administration of N-methyl-N'-nitro-N-nitrosoguanidine and beta-propiolactone to the Muta Mouse: preliminary data on stomach, liver and bone marrow
    D Brault
    Rhone Poulenc Rorer, Drug Safety Department, Vitry sur Seine, France
    Mutat Res 360:83-7. 1996
    ..These data indicate that the Muta Mouse model can be used to predict the gastric specificity of genotoxic carcinogens...